# OnCo record terremoto-biosciences (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/terremoto-biosciences/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "terremoto-biosciences" ;
  schema:name "Terremoto Biosciences"@en ;
  schema:alternateName "Terremoto Biosciences Inc."@en ;
  schema:description "Terremoto Biosciences makes tablets that block AKT1, a growth signal that is switched on in many breast and other cancers, while trying to avoid the side effects of blocking related proteins. Its lead drug, TER-2013, is in an early trial."@en ;
  schema:url <https://onco.cc/companies/terremoto-biosciences/>, <https://terremotobio.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://terremotobio.com/>, <https://terremotobio.com/press-release/terremoto-biosciences-closes-108-million-series-c-financing-to-advance-selective-akt1-inhibitors-in-oncology-and-hereditary-hemorrhagic-telangiectasia/>, <https://clinicaltrials.gov/study/NCT07109726> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/lung-squamous-cell-carcinoma/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/oesophageal-squamous-cell-carcinoma/>, <https://onco.cc/cancers/cervical/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/> ;
  onco:targets <https://onco.cc/targets/akt/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/pten/> ;
  onco:trials <https://onco.cc/trials/nct07109726/> .